BGNE News and Press, BeiGene Ltd. From 03/14/24

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE:...

2024-03-13 11:57:58 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene: Debating On Finally Establishing A Position BeiGene gets FDA accelerated approval for Brukinsa for follicular lymphoma FDA accepts BeiGene license applicat...

BeiGene, Ltd. (NASDAQ: BGNE) is one of today's top gainers. The company's shares have moved 9.13% on the day to $178.7. BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationall...

2024-03-13 08:29:15 ET Read the full article on Seeking Alpha For further details see: KB Financial, BeiGene, Legend Biotech among premarket gainers' pack

Armenia and Nepal are the first of 29 countries to receive BRUKINSA The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, ...

2024-03-08 05:10:00 ET Summary BeiGene's revenue surged 73.7% to $2.46 billion last year. But for all the success with its flagship product, the drug maker was not able to power all the way into the black. Undeterred by the continuing losses, investors welcomed the bumper sale...

2024-03-07 17:23:10 ET More on BeiGene BeiGene: Debating On Finally Establishing A Position FDA accepts BeiGene license application for gastric cancer combo therapy BeiGene gets EU backing for lung cancer therapy Seeking Alpha’s Quant Rating on BeiGene...

BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approval based on positive results from ROSEWOOD trial showing BRUKINSA plus obinutuzumab achieved higher overall response rate versus obinutuzumab...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

Multiple trials underscore the potential of tislelizumab-containing immuno-oncology combinations in a variety of solid tumor settings Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cel...